Business Context and Reporting Period
Protalix Biotherapeutics, Inc. filed this Form 8-K on May 28, 2020, reporting an event that occurred on May 27, 2020. The Company is a Delaware corporation developing investigational product candidates for rare diseases.
Key Financial Metrics
This filing is a Current Report regarding a specific corporate event and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes
The material event reported is the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for pegunigalsidase alfa. This submission was made via the FDA's Accelerated Approval pathway for the proposed treatment of adult patients with Fabry disease. The submission was announced jointly with the Company's development and commercialization partner, Chiesi Global Rare Diseases.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the BLA submission. The filing does not provide specific financial guidance, updated outlooks, or a detailed discussion of risks and contingencies beyond the context of the regulatory submission. Pegunigalsidase alfa is described as a purposefully-designed, long-acting recombinant, PEGylated, cross-linked alpha-galactosidase-A investigational product candidate.
Investor Verification Checklist
- Verify the status of the BLA submission for pegunigalsidase alfa with the FDA.
- Review the full text of the press release attached as Exhibit 99.1 for additional details on the Accelerated Approval pathway.
- Confirm the terms of the partnership with Chiesi Global Rare Diseases regarding commercialization rights.
- Check subsequent filings for any FDA responses or updates on the application status.